Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment
Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS).
Singular Photonics and AMS Technologies to bring advanced SPAD sensors to Europe
Singular Photonics, a developer of image sensor technologies, has announced a strategic partnership with AMS Technologies, a distributor and solution provider for optical technologies.
AI foot scanner could help prevent hospital stays
An at-home 'foot-recognition' scanner could prevent heart failure hospitalisations, a study has found.
DHL eCommerce UK and HubBox collaboration enables retailers to integrate Pickup at Checkout software
DHL eCommerce UK has partnered with HubBox in a bid to make it easy for retailers to offer out-of-home deliveries and enhance the shopper experience with international orders.
Psyomics wins NHS Innovation Accelerator to drive NHS adoption
Digital mental health company Psyomics has announce that its CEO, Dr Melinda Rees, has been awarded a prestigious NHS Innovation Accelerator (NIA) Fellowship.
Woolland steps up to steer fresh growth phase for Closed Loop Medicine
Closed Loop Medicine, a leader in pharmaceutical precision dosing, has promoted Kate Woolland to Chief Executive Officer. She was previously Chief Operating Officer for the company, which has facilities at Babraham Research Campus.
Archer enters partnership with Paragraf for Biochip development
Archer Materials, a company developing quantum technology for medical diagnostics, has signed an agreement with UK graphene-based electronics company Paragraf.
PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics
Barbara Duncan joins as Chair and Stephen Dilly as Non-Executive Director
Strategic appointments support progression of PhoreMost’s next generation degrader pipeline through preclinical development and commercialisation of its GlueSEEKER® platform
British drone startup Hammer Missions secures €1.6 million to expand to USA
London-based Hammer Missions, an AI company innovating how owners, architects, engineers and contractors inspect built structures with drone technology, has raised €1.6 million in new funding to accelerate its AI technology development and strategic expansion into North America.
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
Monument Therapeutics, a precision neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non Executive Chair of the Board, effective immediately, and Dr Heather Preston has joined the company’s advisory Board.
Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network
Meet Jamie Akhtar, CEO and Co-Founder at All-In-One Cybersecurity Platform: CyberSmart
CyberSmart is an all-in-one cybersecurity monitoring, optimisation, training and insurance platform proven to help small businesses defend against cyber threats.
NoBACZ Healthcare launches Ambugreen – a new, waterproof and antibiotic-free gel barrier
Ambugreen is a ground-breaking gel barrier that features unique patented technology.
Momentum Bioscience Moves To Milton Park To Develop Time Critical Sepsis Tests
Momentum Bioscience, a biotech company pioneering rapid sepsis diagnostics, has relocated to Oxfordshire’s Milton Park, the UK’s largest single-ownership innovation community.
Qureight and Remedy Cell to validate RC-0315 in Phase Ib trial for IPF
Qureight will integrate its deep-learning technology into the study, providing imaging core lab services.
Dogtooth appoints Jorge Heraud as chairman
Robotic harvesting specialist appoints Blue River Technology co-founder as new chairman of the board.
Sphere Fluidics rebrands to Sphere Bio
Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions.
Monument Therapeutics secures £850K to advance schizophrenia treatment with MT1988
Neuroscience startup Monument Therapeutics has developed MT1988, a novel fixed-dose combination drug for the cognitive impairment associated with schizophrenia.
Healx doses first subject in Phase II neurofibromatosis type 1 therapy trial
Nearly 20 subjects in the US are being enrolled for the trial.
Oxford Drug Design awarded £1m to progress uUTI treatment
Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy).